Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors

Leukemia volume 17, pages 760–763 (2003)Cite this article

Abstract

Primitive malignant progenitors defined as nonobese diabetic/severe combined immunodeficient (NOD/SCID) leukemia-initiating cells or NOD/SL-IC from patients with acute myeloid leukemia (AML) can be detected and quantitated in sublethally irradiated NOD/SCID mice. However, there is variability in the levels of bone marrow (BM) engraftment obtained after intravenous injection of cells from different AML samples. In the current study, AML cell engraftment in standard NOD/SCID mice was compared to that obtained with NOD/SCID mice transgenic for the human growth factor genes Steel factor (SF), interleukin-3 (IL-3) and granulocyte macrophage-colony-stimulating factor (GM-CSF) (N/S-S/GM/3) as well as β2 microglobulin-null NOD/SCID (N/S-β2m–/–) mice. Three of the eight AML samples that failed to engraft in standard NOD/SCID animals showed easily detectable and up to 70-fold increased in the number of leukemic cells in BM 8–12 weeks post-transplantation in each of the N/S-β2m–/– and N/S-S/GM/3 mouse strains. In two of the four AML samples studied at limiting dilution, the frequency of NOD/SL-IC detected was increased six- and seven-fold. Thus, in these novel mouse strains a broader spectrum of AML patient samples can be evaluated for their progenitor content and potentially studied for their response to innovative therapeutics in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–736.

    Article  CAS  PubMed  Google Scholar 

  2. Ailles LE, Gerhard B, Kawagoe H, Hogge DE . Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761–1772.

    CAS  PubMed  Google Scholar 

  3. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ . Lack of expression of Thy-1 (CD90) on acute myeloid leukaemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 3104–3112.

    CAS  PubMed  Google Scholar 

  4. Blair A, Hogge DE, Sutherland HJ . Most acute myeloid leukaemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71−/HLA-DR−. Blood 1998; 92: 4325–4335.

    CAS  PubMed  Google Scholar 

  5. Blair A, Sutherland HJ . Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit. Exp Hematol 2000; 28: 660–671.

    Article  CAS  PubMed  Google Scholar 

  6. Feuring-Buske M, Hogge DE . Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38− progenitor cells from patients with acute myeloid leukemia. Blood 2001; 97: 3882–3889.

    Article  CAS  PubMed  Google Scholar 

  7. Bonnet D, Bhatia M, Wang JCY, Kapp U, Dick JE . Cytokine treatment of accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant 1999; 23: 203–209.

    Article  CAS  PubMed  Google Scholar 

  8. Terpstra W, Leenen PJ, van den BC, Prins A, Loenen WA, Verstegen MM et al. Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes. Leukemia 1997; 11: 1049–1054.

    Article  CAS  PubMed  Google Scholar 

  9. Rombouts WJ, Martens AC, Ploemacher RE . Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000; 14: 889–897.

    Article  CAS  PubMed  Google Scholar 

  10. Ailles LE, Gerhard B, Hogge DE . Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997; 90: 2555–2564.

    CAS  PubMed  Google Scholar 

  11. Hogge DE, Ailles LE, Gerhard B . Cytokine responsiveness of primitive progenitors in acute myelogenous leukemia. Leukemia 1997; 11: 2220–2221.

    CAS  PubMed  Google Scholar 

  12. Sutherland HJ, Blair A, Zapf RW . Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996; 87: 4754–4761.

    CAS  PubMed  Google Scholar 

  13. Christianson SW, Greiner DL, Hesselton R, Leif JH, Wagar EJ, Schweitzer IB et al. Enhanced human CD4+ T cell engraftment in β2-microglobulin-deficient NOD-scid mice. J Immunol 1997; 158: 3578–3586.

    CAS  PubMed  Google Scholar 

  14. Kollet O, Peled A, Byk T, Ben-Hur H, Greiner D, Shultz L et al. β2 microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 2000; 95: 3102–3105.

    CAS  PubMed  Google Scholar 

  15. Glimm H, Eisterer W, Lee K, Cashman J, Holyoake TL, Nicolini F et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice. J Clin Invest 2001; 107: 199–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 620–625.

    Article  CAS  PubMed  Google Scholar 

  17. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ . Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood 1996; 88: 3765–3773.

    CAS  PubMed  Google Scholar 

  18. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180–191.

    CAS  PubMed  Google Scholar 

  19. Nicolini FE, Cashman JD, Humphries RK, Eaves CJ . Transplantation of human marrow in NOD/SCID mice genetically engineered to continuously produce human IL-3, GM-CSF and Steel Factor (SF) results in increased numbers of human progenitors in the circulation without compromising overall engraftment. Blood 2000; 96: 292a (Abstract).

    Google Scholar 

  20. Feuring-Buske M, Frankel A, Gerhard B, Hogge D . Variable cytotoxicity of diphtheria toxin 388-granulocyte–macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol 2000; 28: 1390–1400.

    Article  CAS  PubMed  Google Scholar 

  21. Cashman JD, Eaves CJ . High marrow seeding efficiency of human lymphomyeloid repopulating cells in irradiated NOD/SCID mice. Blood 2000; 96: 3979–3981.

    CAS  PubMed  Google Scholar 

  22. Guan Y, Ralph S, Hogge DE . Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 2002; 30: 721–728.

    Article  CAS  PubMed  Google Scholar 

  23. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE . A diphtheria toxin–interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002; 62: 1730–1736.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Cancer Institute of Canada with funds from the Terry Fox Run to D Hogge. M Feuring-Buske was supported by a grant from the Deutsche Krebshilfe, Bonn, Germany.

Author information

Authors and Affiliations

  1. The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada

    M Feuring-Buske, B Gerhard, J Cashman, R K Humphries, C J Eaves & D E Hogge

  2. GSF, National Research Center for Environment and Health, Munich, Germany

    M Feuring-Buske

Authors
  1. M Feuring-Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Gerhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Cashman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R K Humphries
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C J Eaves
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D E Hogge
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feuring-Buske, M., Gerhard, B., Cashman, J. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17, 760–763 (2003). https://doi.org/10.1038/sj.leu.2402882

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402882

Keywords

This article is cited by

Search

Advanced search

Quick links